OPNT - Opiant Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
23.50
-0.61 (-2.53%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close24.11
Open24.10
Bid6.90 x 400
Ask25.10 x 100
Day's Range21.35 - 24.76
52 Week Range5.00 - 51.90
Volume163,867
Avg. Volume76,984
Market Cap48.595M
Beta3.34
PE Ratio (TTM)34.26
EPS (TTM)0.69
Earnings DateMar 14, 2018 - Mar 19, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.67
Trade prices are not sourced from all markets
  • Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q1, 2018 By the Numbers : December 7, 2017
    Capital Cube8 days ago

    Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q1, 2018 By the Numbers : December 7, 2017

    Categories: Yahoo FinanceGet free summary analysis Opiant Pharmaceuticals, Inc. reports financial results for the quarter ended October 31, 2017. We analyze the earnings along side the following peers of Opiant Pharmaceuticals, Inc. – GW Pharmaceuticals PLC Sponsored ADR and Arena Pharmaceuticals, Inc. (GWPH-US and ARNA-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more (Read more...)

  • GlobeNewswire11 days ago

    Opiant Pharmaceuticals, Inc. Reports Fiscal First Quarter 2018 Financial Results

    SANTA MONICA, Calif., Dec. 04, 2017-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the fiscal ...

  • Zacks Small Cap Research2 months ago

    OPNT: Looking to Keep Momentum Going into Fiscal 2018

    Opiant Pharmaceuticals, Inc. (OPNT) is a specialty pharmaceutical company developing treatments for substance use, eating disorders, and addiction disorders based on the company’s expertise in opioid receptor antagonists. Opiant currently has one FDA approved drug, NARCAN® Nasal Spray, which is marketed by Adapt Pharmaceuticals through an exclusive collaboration. Fiscal 2017 was a transformative year for Opiant, as the company monetized the royalties for NARCAN® Nasal Spray, uplisted to the Nasdaq stock exchange, strengthened the leadership team with the appointment of a new Chief Financial Officer, and announced encouraging Phase 1 data for OPNT002 in Alcohol Use Disorder (AUD).

  • Is It Time To Buy Opiant Pharmaceuticals Inc (OPNT) Based Off Its PE Ratio?
    Simply Wall St.2 months ago

    Is It Time To Buy Opiant Pharmaceuticals Inc (OPNT) Based Off Its PE Ratio?

    Opiant Pharmaceuticals Inc (NASDAQ:OPNT) trades with a trailing P/E of 12.4x, which is lower than the industry average of 23.5x. While this makes OPNT appear like a great stock toRead More...

  • GlobeNewswire2 months ago

    Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

    SANTA MONICA, Calif, Oct. 13, 2017-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the fiscal ...

  • ACCESSWIRE2 months ago

    Corporate News Blog - Titan Pharma and Opiant Pharma Collaborate to Discover a New Approach for Treatment of Opioid Use Disorder

    LONDON, UK / ACCESSWIRE / October 4, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ), following which we have ...

  • Titan Pharmaceuticals and Opiant Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder Treatment
    PR Newswire2 months ago

    Titan Pharmaceuticals and Opiant Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder Treatment

    SOUTH SAN FRANCISCO, Calif., Oct. 2, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) and Opiant Pharmaceuticals, Inc. (OPNT) today announced a collaboration to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The companies will conduct a feasibility assessment of a subcutaneous implant using Titan's proprietary ProNeura™ sustained release technology to administer an opioid antagonist. A product that delivers non-fluctuating, therapeutic levels of an opioid antagonist, continuously for up to 6 months, may be ideally suited for the prevention of opioid relapse and overdose.

  • GlobeNewswire2 months ago

    Opiant Pharmaceuticals and Titan Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder Treatment

    SANTA MONICA, Calif., Oct. 02, 2017-- Opiant Pharmaceuticals, Inc. and Titan Pharmaceuticals, Inc. today announced a collaboration to explore development of a novel approach to the prevention of opioid ...

  • GlobeNewswire3 months ago

    Opiant Pharmaceuticals, Inc., CEO Roger Crystal, M.D., to Present to President's Commission on Combating Drug Addiction and the Opioid Crisis

    SANTA MONICA, Calif., Sept. 25, 2017-- Opiant Pharmaceuticals, Inc.,, today announced that Chief Executive Officer Roger Crystal, M.D., has been invited to testify before the President's Commission on ...

  • Forbes3 months ago

    Opiant Up Nearly 30% On Favorable Zacks Report

    Opiant Pharmaceuticals jumped nearly 30% yesterday on a favorable report from Zacks, making it the forth largest position in Todd Hagopian's Biotech Fund. Here's what Todd thinks of the news.

  • Zacks Small Cap Research3 months ago

    OPNT: Estimating When Royalties to NARCAN® Nasal Spray Revert Back to Opiant

    On December 15, 2016, Opiant Pharmaceuticals, Inc. (OPNT) announced an agreement with SWK Holdings Corporation whereby SWK acquired the rights to certain royalty and milestone payments related to the sale of NARCAN® Nasal Spray for an initial payment of $13.7 million and the potential for an additional $3.75 million if certain future net sales milestones are met. On August 10, 2017, Opiant announced an additional $3.75 million payment from SWK related to the royalty monetization agreement related to the sale of NARCAN® Nasal Spray signed between Opiant and SWK in December 2016. According to the agreement, the $3.75 million payment was due to Opiant upon Adapt Pharma recording $25 million in cumulative net sales of NARCAN® Nasal Spray for any two consecutive quarters from Oct. 1, 2016 to Sep. 30, 2017.

  • ACCESSWIRE3 months ago

    Corporate News Blog - Opiant Delivers Update on NARCAN Nasal Spray; Surpasses $25 Million Net Sales in H1 2017

    Research Desk Line-up: SeaChange Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Opiant ...

  • Zacks Small Cap Research4 months ago

    OPNT: Uplists to NASDAQ

    By David Bautz, PhD NASDAQ:OPNT Opiant Uplists to the Nasdaq Stock Exchange On August 28, 2017, Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced its shares of common stock were approved for listing ...

  • Zacks Small Cap Research4 months ago

    OPNT: Receives Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization

    On August 10, 2017, Opiant Pharmaceuticals Inc. (OPNT) announced an additional $3.75 million payment from SWK Holdings Corporation related to the royalty monetization agreement related to the sale of NARCAN® Nasal Spray signed between Opiant and SWK in December 2016. According to the agreement, the $3.75 million payment was due to Opiant upon Adapt Pharma recording $25 million in cumulative net sales of NARCAN® Nasal Spray for any two consecutive quarters from Oct. 1, 2016 to Sep. 30, 2017. The royalty monetization agreement with SWK stipulates that SWK will receive all royalties on the sale of NARCAN® Nasal Spray up to $26.25 million dollars.

  • TheStreet.com5 months ago

    Opiant Pharmaceuticals Looks to Create a Heroin Vaccine and Treat Addictions

    Overdoses kill 91 people a day.

  • Zacks Small Cap Research5 months ago

    OPNT: Encouraging Data From P1 Study of OPNT002 in Alcohol Use Disorder

    On July 19, 2017, Opiant Pharmaceuticals Inc. (OPNT) announced results from a Phase 1 study of OPNT002, an intranasally (IN) administered formulation of the opioid antagonist naltrexone hydrochloride. Opiant is developing OPNT002 for the treatment of Alcohol Use Disorder (AUD). The Phase 1 study examined the effects of Intravail® on the pharmacokinetic properties of IN naltrexone in healthy volunteers.